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Abstract Botulinum neurotoxin A (BoNT A) is the first-
line treatment for cervical dystonia. However, although
BoNT A has a favorable safety profile and is effective in
the majority of patients, in some cases the treatment out-
come is disappointing or side effects occur when higher
doses are used. It is likely that in such cases either the
target muscles were not injected accurately or unintended
weakness of non-target muscles occurred. It has been
demonstrated in clinical trials for spastic movement dis-
orders that sonography-guided BoNT A injections could
improve treatment outcome. As the published evidence for
a benefit of sonography-guided BoNT injection in patients
with cervical dystonia is scarce, it is the aim of this review
to discuss the relevance of sonography in this indication
and provide a statement from clinical experts for its use.
The clear advantage of sonography-guided injections is
non-invasive, real-time visualization of the targeted mus-
cle, thus improving the precision of injections and poten-
tially the treatment outcomes as well as avoiding adverse
effects. Other imaging techniques are of limited value due
to high costs, radiation exposure or non-availability in
clinical routine. In the hands of a trained injector, sonog-
raphy is a quick and non-invasive imaging technique.
Novel treatment concepts of cervical dystonia considering
the differential contributions of distinct cranial and cervical
muscles can reliably be implemented only by use of
imaging-guided injection protocols.
Keywords Cervical dystonia  Botulinum toxin 
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Introduction
Botulinum neurotoxin A (BoNT A) is the first-line treat-
ment for cervical dystonia (CD) and focal spasticity
(Simpson et al. 2008, Truong and Jost 2006). The efficacy
and safety of BoNT A has been demonstrated in numerous
clinical studies leading to licensed use in many countries
worldwide (Costa et al. 2005; Kamm and Benecke 2011;
Simpson et al. 2008; Ade-Hall and Moore 2000; Truong
and Jost 2006; Hallett et al. 2013; Esquenazi et al. 2013).
Several studies (at least for upper and lower limbs)
showed a low accuracy of muscle localization when using
anatomical landmarks only (Chin et al. 2005; Molloy et al.
2002; Schnitzler et al. 2012; Yang et al. 2009; Henzel et al.
2010). The accuracy of manual needle placement was not
acceptable for the majority of target muscles. In conse-
quence, it was concluded from these studies that ultrasound
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(US) could be considered as a valuable adjunct for muscle
localization in patients with spasticity and that US can
improve accuracy of BoNT A placement. However, to our
knowledge, no studies have addressed the accuracy of
needle placement in cervical muscles up to now.
With US guidance muscles can be targeted quickly and
reliably by a non-invasive technique. US is of special value
as the injected muscles differ in size, and deep-seated
muscles require a different approach compared to superfi-
cial muscles (Fietzek et al. 2010; Gervasio et al. 2011). The
US technique is already widely applied in neuropediatric
care. For the treatment of spasticity injection control by US
guidance has been recommended in several consensus
statements (e.g., Wissel et al. 2011; Heinen et al. 2010). An
improved clinical outcome could be demonstrated for US-
guided BoNT A injections in children with cerebral palsy
(Kwon et al. 2010; Py et al. 2009) and adults with spasticity
after stroke compared to manual needle placement in two
randomized controlled trials (Picelli et al. 2012a, 2013). In
the lower limb, one of these studies (Picelli et al. 2012a)
showed a trend for superiority of US guidance compared to
electrical stimulation. In another study, neither manual
needle placement nor electrical stimulation showed com-
plete accuracy when compared to US (Picelli et al. 2012b).
In cervical dystonia, most clinical studies investigated
the application of electromyography (EMG). In these
studies, EMG was used not only for injection guidance but
as well for muscle selection. Nevertheless, a recent review
did not show an overall better outcome compared to clin-
ical muscle selection and anatomical needle placement
(Nijmeijer et al. 2012).
For the application of US guidance in cervical dystonia,
only very few publications of non-controlled studies or
case reports in a low number of patients are available
which refer mainly to deep, difficult accessible muscles,
e.g., longus colli or obliquus capitis inferior (OCI) (Bhi-
dayasiri 2011; Fujimoto et al. 2012; Sung et al. 2007; Lee
et al. 2009). Currently, there are no controlled comparative
clinical studies of BoNT A injection according to anatomic
landmarks versus sonography-guided injection in this
indication. However, a recently published study although
in a low number of patients with cervical dystonia provides
evidence that US guidance of BoNT A injection in the
sternocleidomastoid (SCM) muscle could reduce the rate of
dysphagia (Hong et al. 2012). The authors concluded from
their observations that recurrent dysphagia could reliably
be eliminated by keeping the BoNT A solution within the
SCM.
It is the aim of this review to discuss the application of
US for injection control as well as the advantages and
future perspectives of sonography-guided BoNT A injec-
tions in patients with cervical dystonia based on the
available literature and our own experience.
Differentiation from other techniques for injection
control
Other techniques for injection control have been investi-
gated in cervical dystonia, however several limitations
have to be taken into account.
Although the use of computed tomography (CT) has
been published in a small number of patients (Bhidayasiri
2011; Sung et al. 2007; Lee et al. 2009; Herting et al.
2004), its use is limited to a clinical setting where CT is
accessible. Further on, CT is too expensive for frequent use
in daily practice, it is not dynamic, and patients are
exposed to radiation. Despite comparable anatomic preci-
sion of CT and US, the latter displays the major drawback
for its use in long-term treatment of patients with cervical
dystonia. The disadvantage of radiation exposure also
applies to fluoroscopy (Glass et al. 2009) which requires
multiple intramuscular injections of iodine-containing
contrast medium.
Positron emission tomography (PET) has been used in
two studies to identify hypermetabolic and presumably
dystonic muscles, whereas injection was performed under
CT or ultrasound guidance (Sung et al. 2007; Lee et al.
2009). PET therefore represents a rather diagnostic
method, than a method for injection control.
Several studies have dealt with the use of EMG for
BoNT A injection in cervical dystonia. All these studies
should be interpreted with caution as EMG was simulta-
neously used for muscle selection. Nevertheless, only one
randomized controlled trial showed better results for
combined EMG selection and EMG guidance compared to
clinical muscle selection with anatomical needle placement
(Comella et al. 1992). A pooled analysis of 28 studies of
which 17 used clinical evaluation to identify dystonic
muscles and 11 used EMG for selection, and guidance
showed better results for the EMG approach regarding pain
reduction (-40.3 vs.-32.5 %). However, improvement
was lower for EMG compared to clinical evaluation for
clinical rating scales like the TSUI score (-31.9 vs.
-43.7 %) (Nijmeijer et al. 2012). It has to be taken into
account that positioning of the EMG needle in these
approaches was performed according to anatomic land-
marks. The placement of the EMG needle tip into a specific
muscle is thereby almost impossible to verify, as selective
voluntary activation of neck muscles is not possible and
might be additionally superimposed by dystonic activity
from adjacent muscles. EMG therefore serves more as a
‘‘functional’’ but not anatomical guidance as the assign-
ment of EMG activity to specific muscles is flawed by the
same anatomic inaccuracy as needle placement according
to anatomical landmarks. Nevertheless, these shortcomings
might be circumvented by combining EMG with ultra-
sound guidance (see also below). Finally ‘‘searching’’ for
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dystonic EMG activity is associated with additional dis-
comfort and pain for the patient and extra costs for the
EMG needle have to be taken into account.
In cervical dystonia, electrical stimulation is not feasible
because for neck muscles the response to the stimulus is
not specific enough.
Although CT (but not EMG) shows comparable ana-
tomic precision as US, the latter is a non-invasive tech-
nique causing no additional discomfort for the patient nor
exposing the patient to radiation or any further risks. US
allows real-time visualization of muscles and the adjacent
anatomical structures so that the entire injection procedure
of BoNT A can be followed.
Utility and advantages of US-guided injections
Availability of US in central Europe neurological clinics is
high as neurovascular ultrasound is part of clinical routine
diagnostics and almost all clinicians are familiar with the
US machine on-site. Detailed recommendations on the
technical requirements, procedure, and documentation of
US-guided BoNT injection have been recently published
(Walter and Dressler 2014).
The obvious advantage of US is anatomic precision with
accurate, safe, and optimal targeting of BoNT A injections in
the affectedmuscles.With US, almost all neck muscles can be
precisely visualized in themajority of patients. Figure 1 shows
commonly injected muscles as the splenius capitis, sterno-
cleidomastoideus, semispinalis capitis, and levator scapulae
muscles (Fig. 1a, b), aswell asmore difficult accessible, small,
or deeper located muscles like the longus colli, longus capitis,
scalene, and obliquus capitis inferior and superior muscles
(Fig. 1c, d, e). These neck muscles lie in close proximity to
eachother rendering false injections in adjacentmuscles likely.
Table 1 displays typical injection errors and summarizes the
clinical experiences from the authors.
The application of US as injection control avoids
unintended muscle weakness due to diffusion of BoNT A
into adjacent muscles and in consequence reduces the
incidence of adverse reactions. This is especially important
in cervical dystonia, as neck muscles might be small or thin
and lie in close proximity to each other. Hong et al. 2012
report five cases of preselected patients who met criteria for
cervical dystonia and subsequent dysphagia after EMG-
guided injections. Dysphagia could be completely elimi-
nated in these patients by addition of ultrasound guidance.
The same might be especially true for avoidance of unin-
tended weakness of neck extensor muscles.
US is also indispensable when case-specific anatomic
conditions are present such as obesity or very pronounced
neck muscles. In addition, muscle atrophy can occur in
consequence of previous treatments and even muscles like
the splenius capitis or trapezius, which are usually injected
without imaging guidance, can become very thin, thus
putting the attending physician at risk to inject too deep.
Furthermore, the application of US helps to prevent
injection errors in blood vessels and nerves as summarized
in Table 1. Compared to injections in the extremities like
in spasticity treatment, this might be of special importance
in CD as injections in lateral cervical muscles bear a high
risk for injuries of adjacent anatomical structures (e.g.,
carotid artery, thyroid truncus, internal and external jugular
vein, vagal nerve, phrenic nerve, and brachial plexus).
With injections in the dorsal neck region such as the
obliquus capitis inferior muscle, the vertebral artery or the
spinal canal can be erroneously injected. Furthermore,
sonography-guided injections may reduce the bleeding risk
in patients receiving anticoagulant treatment.
Besides, anatomically precise injection of typically
treated superficial muscles, US guidance enables injection
of up to now not routinely treated deep cervical muscles,
which contribute to a broad range of neck movements and
are involved in complex forms of cervical dystonia (Bhi-
dayasiri 2011). These deep muscles include prevertebral
muscles for primary neck flexion, lateral vertebral muscles
for shoulder elevation, neck and head tilt, and a posterior
group of muscles for neck extension (Fig. 1c, d). Some
complex forms of cervical dystonia with involvement of
deep cervical muscles are only poorly accessible by routine
BoNT A therapy. Table 1 provides an overview of the
relevance of US for location of different muscles, which
can be affected in patients with cervical dystonia.
The implementation of more differentiated clinical
concepts distinguishing between individual contributions
of the distinct neck and head muscles (-collis/-caput con-
cept, Reichel 2011) gives rise to the need of a visualization
method for precise differentiation and localization of the
target muscle. The successful realization of this more
realistic phenomenological approach is only feasible with
highly controlled and precise US-guided injections.
Moreover, US guidance offers the potential for dose
reduction and a decrease of the total number of injections/
injected muscles—factors that are potentially reducing the
risk of producing neutralizing antibodies and therefore ensure
long-term efficacy of BoNTA treatment in cervical dystonia.
Finally, US guidance ensures a highly standardized
injection procedure resulting in a stable effect, better
comparability between different injection sessions, and
consistency in case of change of the treating physician.
This circumstance is of special importance for cervical
dystonia patients being treated for many years.
US for anatomical knowledge
A secondary but important effect of using US is the
improvement of anatomical knowledge of the injecting
Relevance of sonography for botulinum toxin treatment 1459
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physician. This is especially meaningful and indispensable
for beginners who need to be trained in the specific and
complex anatomy of neck muscles. However, consolidation
of anatomical knowledge by applying US is also reason-
able for experienced therapists. Finally, even patients who
are usually injected without US guidance may profit from
improved anatomical understanding of the treating
physician.
Disadvantages of US
Currently, there are only a few practical drawbacks. The
immediate availability of ultrasound equipment is not
always and everywhere guaranteed, and there is a lack of
reimbursement, especially in comparison to EMG. The
additional expenditure of time for application of US can be
reduced by training programs.
Clinical studies and future perspectives
In general, efficacy of BoNT A treatment in cervical dys-
tonia is high (e.g., Costa et al. 2005; Hallett et al. 2013).
Nevertheless, there is a potential for further improvements,
and refined clinical and diagnostic concepts warrant pro-
spective clinical studies. As an optimized BoNT A treat-
ment is based on (a) accurate identification of involved
muscles and (b) accurate injection of identified muscles,
US guidance should be included in future studies to ensure
standardized injection procedures as well as proper tar-
geting of identified muscles. Although diagnostic applica-
tion of US for muscle identification is not within the scope
of this review, US might be used for detection of muscle
hypertrophy. Furthermore, the combination of US and
EMG could overcome the shortcomings of EMG regarding
anatomic precision and would allow an accurate assign-
ment of dystonic or tremulous activity to specific muscles
(Schramm et al. 2014).
Conclusions and expert statement
US is an increasingly available, non-invasive, and inex-
pensive method, which has clear advantages over other
techniques for injection control in BoNT A treatment of
Fig. 1 Sonographic appearance of frequently injected muscles
(mainly a, b) and more difficult accessible, small, or deeper located
muscles (mainly c, d, e). Muscles: IH infrahyoid, SCM sternoclei-
domastoideus, SA scalenus anterior, SMP scalenus medius posterior,
LEV levator scapulae, TRA trapezius, SEM semispinalis capitis, SPL
splenius capitis, OCI obliquus capitis inferior, LC longissimus capitis,
LCo longus colli, LCa longus capitis, RMi rectus capitis posterior
minor, RMa rectus capitis posterior major, and OCS obliquus capitis
superior. Others are CA carotid artery, BP brachial plexus, VC5
vertebra C5, RC5 root C5, and VN vagus nerve
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cervical dystonia. It facilitates anatomically precise and
reproducible injections in specific muscles, therefore car-
rying the potential of enhancing efficacy and safety of
BoNT A treatment in cervical dystonia. It is a valuable
method to improve anatomical knowledge and the quality
of future clinical studies.
The implementation of US guidance in clinical routine
will also lead to an improvement of BoNT A injection
schemes and our functional understanding in cervical
dystonia, because only a precise injection in the target
muscles allows judgement of the relevance of the
respective muscles for the dystonic pattern. US therefore
facilitates the correct identification of the functionality of
muscles in relation to patient phenomenology. A valid
concept of the role of different muscles in multidimen-
sional movement disorders can only be developed if there
is no doubt which muscles have really been injected or at
least if the uncertainty can be reduced as far as possible.
This has been pointed out by Reichel (2011) in con-
nection with the -caput/-collis concept using CT, but is
applicable for sonography, as this method can be used
repeatedly in patients without putting them at risk of
radiation.
Therefore, from the perspective of the authors there is
no convincing reason why US guidance for injection
control should not become standard in BoNT A treatment
of cervical dystonia.
In conclusion, due to the advantages of US-guided
BoNT A injections and the experience of the authors in
clinical practice, the authors summarize their opinion as
follows:
– Beginners should learn the specific anatomy of neck
muscles and exact targeting of BoNT A treatment by
application of US.
– Expertise in US guidance should be available at each
BoNT A treatment center.
– In the opinion of the authors, the routine use of US
injection guidance could be recommended in general.
– Preferably, US guidance should be applied in the
following cases:
• Presence of individual anatomic conditions (pro-
nounced neck muscles, atrophy, and obesity)
• Occurrence of adverse events after BoNT A injec-
tions (especially dysphagia and unintended
weakness)
• Presence of complex dystonic patterns with a high
probability of involvement of deeper located mus-
cles which are more difficult to access (see Tab. 1;
relevance ??/???).
Table 1 Relevance of ultrasonography (US) for injection of muscles in cervical dystonia
Muscle Relevance of US
for muscle
location
Relevance of US to avoid
adverse reactions or injuries





Sternocleidomastoideus ? ?? (Dysphagia) Carotid artery
Longus colli/capitis ??? ??? Carotid artery, jugular vein, vagal
nerve, phrenic nerve
Scalene muscles ??? ??? Levator scapulae Brachial plexus, external jugular
vein




Splenius capitis ? (Injection often
too deep)



















??? ??? Semispinalis capitis, other
small neck muscles
Vertebral artery, N. occipitalis
major, spinal canal
Trapezius ? Levator scapulae; splenius
capitis, Semispinalis
Might be frequently very thin,
especially during continuous
treatment
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• Secondary non-responders without neutralizing
antibodies against BoNT A
– US guidance should be included in future clinical
studies.
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